ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0744

Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
Abstract Number: 0745

Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis
Abstract Number: 0746

The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis
Abstract Number: 0747

Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica
Abstract Number: 0748

Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT
Abstract Number: 0749

Impact of Sprifermin on Denuded Areas of Subchondral Bone (dABs): A Post Hoc Analysis of the FORWARD Study
Abstract Number: 0750

Multispectral Optoacoustic Tomography of the Entheses Reveals Common Metabolic and Architectural Tissue Patterns in Psoriasis and Psoriatic Arthritis Independent of Inflammation
Abstract Number: 0751

Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Abstract Number: 0752

Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators
Abstract Number: 0753

Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System
Abstract Number: 0754

Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis
Abstract Number: 0755

Changes in Rheumatology Providers’ Perceptions of Telehealth Appropriateness from 2021 to 2022
Abstract Number: 0756

Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative
Abstract Number: 0757

Identification of 23 Novel COPA Rare Exonic Non-Synonymous Variants and Their Associated Autoimmune and Inflammatory Clinical Phenotypes Among 53,364 Individuals
Abstract Number: 0758

Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].